Intellia Therapeutics Files 8-K
Ticker: NTLA · Form: 8-K · Filed: Jun 16, 2025 · CIK: 1652130
Sentiment: neutral
Topics: filing, sec
TL;DR
Intellia filed an 8-K, check for updates.
AI Summary
Intellia Therapeutics, Inc. filed an 8-K on June 16, 2025, reporting events as of June 15, 2025. The filing primarily concerns Regulation FD disclosures, other events, and financial statements/exhibits, with no specific material events or financial figures detailed in the provided text.
Why It Matters
This filing indicates Intellia Therapeutics is providing updates or disclosures to the SEC, which could contain material information for investors.
Risk Assessment
Risk Level: low — The provided text is a standard 8-K filing notification and does not contain specific material events or financial data that would indicate a change in risk.
Key Players & Entities
- Intellia Therapeutics, Inc. (company) — Registrant
- 001-37766 (company) — SEC File Number
- 36-4785571 (company) — IRS Employer Identification No.
- 40 Erie Street , Suite 130 Cambridge , Massachusetts 02139 (company) — Principal Executive Offices Address
FAQ
What is the primary purpose of this 8-K filing for Intellia Therapeutics, Inc.?
The filing is a Current Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934, covering Regulation FD Disclosure, Other Events, and Financial Statements and Exhibits.
What is the date of the earliest event reported in this filing?
The date of the earliest event reported is June 15, 2025.
What is Intellia Therapeutics, Inc.'s state of incorporation?
Intellia Therapeutics, Inc. is incorporated in Delaware.
What is the business address of Intellia Therapeutics, Inc.?
The business address is 40 Erie Street, Suite 130, Cambridge, Massachusetts 02139.
What is the SEC file number for Intellia Therapeutics, Inc.?
The SEC file number is 001-37766.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on June 16, 2025 regarding Intellia Therapeutics, Inc. (NTLA).